New sequencing technologies are facilitating the development of large panels of genes that can be screened for mutations in patients with suspected hematological malignancies. Emerging evidence, however, has indicated that some malignancyassociated mutations are detectable in the general population, raising questions about the utility of broad mutation screening of peripheral blood or bone marrow DNA as a diagnostic tool. Analysis of intensity data tracks from single-nucleotide polymorphism (SNP) array analysis of peripheral blood DNA from older individuals (typically 460 years) in population cohorts has revealed large somatically acquired chromosomal duplications, deletions and regions of acquired uniparental disomy (aUPD; also known as copy number neutral loss of heterozygosity) similar to those seen in individuals with a hematological malignancy. [1] [2] [3] [4] Such variants are typically present in a proportion of peripheral blood cells at a specific time-point, but their frequency can increase or decrease over time and even disappear, suggesting a dynamic pattern of clonal change.
1 Consistent with this data, mutations in genes, such as TET2, DNMT3A, ASXL1 and JAK2, that are often mutated in myeloid malignancy, have also been described in elderly individuals with no evidence of hematological malignancy. [5] [6] [7] [8] Increasing age is accompanied by the changes to the hematopoietic stem cell compartment, a process known as myeloid shift, with a bias toward the myeloid lineage at the expense of the lymphoid lineage. 9 In addition, acquired skewing of X-chromosome inactivation patterns in elderly women suggests that there is a reduction in stem cell usage over time that might in principle be stochastic or driven by subclinical clonal expansion. 10 These combined factors may help to explain the higher frequency of myeloid neoplasia in the elderly population.
To investigate the presence of mutations in elderly populations further, we studied two independent cohorts: (i) the Uppsala Longitudinal Study of Adult Men (ULSAM), an ongoing epidemiologic study of all available men born between 1920 and 1924 in Uppsala County, Sweden who have been analyzed by SNP arrays; 1, 4 and (ii) 56 elderly women with normal blood counts and paired DNA from both neutrophils and T cells. 10 We have previously reported the finding that mosaic loss of the Y chromosome in peripheral blood leukocytes is associated with shorter survival and higher risk of cancer, on the basis of the analysis of Illumina (San Diego, CA, USA) 2.5 M Omni Chip SNP data of 1153 ULSAM participants. 4 Further analysis of this SNP data identified 15 cases (1.3%) with regions of likely autosomal aUPD 410 Mb in size (median size 27 Mb; range 13-103 Mb). Two observations each were seen at 11p, 19q and 22q, and one observation each at 1p, 4q, 6p, 9p, 9q, 11q, 14q, 15q and 17p. Although no obvious recurrences were identified, many of these regions include somatically mutated driver genes that are associated with aUPD in hematological malignancies. 11 Of the 15 individuals with aUPD, 2 had been diagnosed with a hematological disorder at the time of sampling: one with JAK2 V617F-positive polycythemia vera (9p aUPD) and the other with chronic lymphocytic leukemia (17p aUPD; TP53 status not tested). The 13 remaining individuals had normal blood counts.
As aUPD of chromosome 4 is associated with inactivating TET2 mutations, 11 the case with chromosome 4 aUPD (ULSAM-697) was screened for possible abnormalities in this gene. This revealed a 21-bp deletion that removes the 3′ end of exon 4 and is thus very likely to be deleterious (Figure 1 ). The mutation was present in peripheral blood samples taken at 71, 88 and 90 years of age, but was clearly somatic as it was not detected in CD19+ B cells ( Figure 1 ). We have previously reported the SNP array data showing that ULSAM-697 had readily apparent chromosome 4q aUPD in nucleated blood cells at the ages of 82, 88 and 90 but not at the age of 71. 1 Reinspection of the array data indicated that chromosome 4q aUPD was just visible at the age of 71, at a level of o 10% nucleated cells. Overall, these data indicate that this individual thus had a large heterozygous mutant TET2 clone at the age of 71, but by the age of 82 a prominent homozygous mutant TET2 subclone had emerged. Peripheral blood counts at all time points were normal, and there was no other indication of a hematological disorder. Therefore, for nearly 20 years, this individual carried a somatic TET2 mutation, an initiating event for a hematological malignancy that evolved to homozygosity without the development of any obvious hematological abnormality.
Of note, the level of aUPD4q in ULSAM-697 was very similar at 82 and 88 years of age (58% of nucleated blood cells), but had significantly decreased to 30% of cells at the age of 90.
1 Although it is difficult to accurately quantify deletions directly from the sequence data, visual inspection of the mutant electropherograms suggests that the TET2 mutation level rose and fell in line with the changing aUPD (Figure 1 ). Cell fractionation studies at the age of 90 showed that granulocytes and CD4+ T cells had similar levels of aUPD4q to total nucleated cells, but aUPD was not seen in CD19+ B cells. 1 Remarkably, follow-up analysis at the age of 91 (peripheral blood counts still normal) showed that the level of aUPD in nucleated blood cells had further decreased to just below 30% and was no longer detectable in CD4+ T cells (data not shown).
MPL and CBL mutations have been associated with aUPD at 1p and 11q, respectively, but we did not detect mutations in the known mutational hotspots of these genes in the two affected ULSAM cases. For the other regions, mutational targets associated with aUPD have not yet been identified. 11 Next, we analyzed a cohort of 56 hematologically normal older women, median age 81 years (range 75-95 years), with paired DNA available from purified neutrophils and T cells. 10 Initially we screened neutrophil DNA for JAK2 V617F and mutations in DNMT3A (exons 18-23) and TET2 (all coding exons) by high resolution melt followed by Sanger sequencing. 12 Subsequently, the samples were analyzed on an Illumina Miseq using either the Illumina Trueseq Custom Amplicon in-house designed panel of genes known to be mutated in myeloid neoplasia (all or selected exons of ASXL1, CBL, CSF3R, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, PHF6, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, TET2, TP53 and U2AF1) or by the Illumina TruSight Myeloid Sequencing Panel (catalog number FC-130-1010). T-cell DNA was only analyzed in cases with sequence variants in the target genes. Overall, combining the Sanger sequencing and MiSeq data, 6 of 56 (11%) individuals were found to carry relevant mutations: DNMT3A variants in two cases at allele frequencies of 24 and 34%, five TET2 variants in four individuals at allele frequencies varying between 4 and 47%, and an SRSF2 variant at 19% (Table 1) . Of these, the DNMT3A p.R882C and SRSF2 p.P95L mutations are both known to be recurrent and frequent in myeloid neoplasia, and one of the TET2 mutations is a frameshift mutation and therefore highly likely to be deleterious. All the abnormalities were either absent or markedly reduced in T cells from the same patient, and the latter may simply reflect the low-level presence of contaminating myeloid cells. Therefore, it is likely that all these mutations were somatically acquired.
Overall, our results concur with the findings of other populationbased studies [5] [6] [7] [8] that a subset of myeloid neoplasia-associated mutations is present in a significant minority of the elderly population who have no clinical manifestations of a hematological disorder. In one such study of whole-exome sequencing data from 17 182 individuals, 160 genes recurrently mutated in lymphoid and myeloid cancers were selected for targeted reanalysis, revealing 805 candidate somatic variants in 73 genes in 746 individuals, mostly without an associated hematological phenotype. 8 It is also now clear that the presence of a somatic mutation increases the risk of development of a hematological Letters to the Editor malignancy with reported hazard ratios of 10.1-12.89. 2, 7, 8 In addition to conferring a risk of subsequent disease development, which our data suggest might be refined by analysis of different blood cell types, findings such as these clearly have implications for the interpretation of whole exome or genome sequencing in elderly individuals, and introduce some uncertainty into the assumption that the mutational landscape of the peripheral blood is representative of that of the germline.
